Bausch Health Companies Inc. Revenue & Financials

Bausch Health Companies Inc. reported $8.9 billion in global revenue for FY2024, representing a 2% increase at constant currency compared to FY2023, driven by the continued robust commercial scaling of the Xifaxan franchise across global markets and the expansion of its label into new gastroenterology indications. The company's operating income surged to $1.8 billion, reflecting a highly efficient cost structure that delivered a 72% gross margin, one of the highest in the global specialty pharmaceutical industry. Net income reached $450 million, while free cash flow generation remained exceptionally strong at $2.1 billion, providing the financial flexibility to fund a $1.2 billion R&D budget and execute strategic debt retirement. The FY2024 financial results highlight a company in the midst of a successful deleveraging transition. While the growth rate of the core Xifaxan franchise has begun to normalize as it reaches saturation in eligible patient populations, the combined sales of Xifaxan ($3.1 billion) and the early commercial contributions from the Ortho Dermatologics portfolio demonstrated that the company's next generation of assets is beginning to achieve commercial scale. The company's gross margin remained stable at approximately 72%, reflecting the pricing power of its patented portfolio despite increasing manufacturing costs for complex aesthetic devices and the impact of international pricing concessions. Selling, general, and administrative expenses were tightly controlled, growing at a slower rate than revenue, which contributed to the margin expansion. The balance sheet remains heavily leveraged but structurally improving, with $15.5 billion in total long-term debt, allowing Bausch Health to maintain a systematic debt retirement program while executing a $500 million acquisition of early-stage dermatology assets. This capital allocation strategy is designed to support the credit rating during the transition period from the Valeant era to the Bausch Health era, signaling management's confidence in the long-term cash generation capabilities of the specialty pharma model. The FY2024 financial performance validates the strategic decision to spin off Bausch + Lomb, as the elimination of the complex intercompany debt guarantees has significantly improved the company's overall financial flexibility and reduced its exposure to the highly competitive eye care market. The detailed breakdown of the FY2024 income statement reveals the underlying drivers of this financial success. Net sales of $8.9 billion were composed of $5.8 billion from the US market, $1.5 billion from Europe, $1.0 billion from Latin America, and $0.6 billion from the rest of the world. The US market remains the most profitable region, contributing approximately 65% of total revenue but an even higher percentage of operating profit due to the significantly higher pricing power for innovative therapies in the United States compared to Europe and emerging markets. The cost of goods sold (COGS) was $2.5 billion, resulting in a gross profit of $6.4 billion and a gross margin of 71.9%. This high gross margin is characteristic of the specialty pharmaceutical industry and reflects the relatively low marginal cost of manufacturing small molecule drugs and biologics once the initial capital-intensive manufacturing facilities have been built and the regulatory approvals have been obtained. Research and development expenses totaled $1.2 billion, representing 13.5% of net sales. This substantial R&D investment is critical for maintaining the company's competitive position and driving future growth, and it is allocated across a diverse portfolio of early-stage discovery programs, Phase I and II clinical trials, and large-scale Phase III registrational studies for tapinarof and other dermatology assets. Selling, general, and administrative (SG&A) expenses were $3.2 billion, or 36.0% of net sales, reflecting the significant commercial investment required to launch and support the company's growing portfolio of dermatology therapies and navigate the complex PBM rebate landscape in the US. The operating income of $1.8 billion was achieved after deducting amortization of intangible assets of $0.8 billion and other operating income/expenses, resulting in an operating margin of 20.2%. This exceptional margin performance is a testament to the company's rigorous cost management practices and the high operating leverage inherent in the specialty pharmaceutical business model. The net income of $450 million was achieved after deducting income taxes of $120 million and interest expense of $850 million, resulting in an effective tax rate of 21.1%, which is slightly below the statutory Canadian rate due to the favorable geographic mix of the company's profits and the utilization of various tax credits and incentives. The strong cash flow generation of $2.1 billion provided the company with the financial flexibility to return $1.8 billion to debt retirement, while also funding $500 million in strategic acquisitions and capital expenditures. The balance sheet at the end of FY2024 showed total assets of $32.5 billion, total liabilities of $28.1 billion, and total equity of $4.4 billion, resulting in a debt-to-equity ratio of 3.5, which is significantly improved from the 2016 peak but still reflects the highly leveraged nature of the corporate structure.